ERLOCIP ERLOTINIB TABLETS

Get a Price/Quote

ERLOCIP ERLOTINIB TABLETS Specification

Dosage Form
Tablet

Salt Composition
Erlotinib Hydrochloride

Origin
Pharmaceutical

Feature
High efficacy, oral administration, specific for EGFR mutation

Ingredients
Erlotinib Hydrochloride, Excipients

Application
Cancer Treatment

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits Epidermal Growth Factor Receptor (EGFR)

Storage Instructions
Store below 30C in a dry place, protect from light

Shelf Life
24 Months

ERLOCIP ERLOTINIB TABLETS Trade Information

Packaging Details
PACK OF 30 CAPSULES

Main Domestic Market
All India

About ERLOCIP ERLOTINIB TABLETS

Erlocip-Erlotinib

Erlocip contains erlotinib and belongs to a class of medications called kinase inhibitors.

INDICATION

Erlocip is used for the treatment of non-small cell lung cancer.
Erlocip is used in combination with gemcitabine for the treatment of pancreatic cancer that has spread to nearby tissues or to other parts of the body.

MECHANISM OF ACTION : Erlocip works by blocking the action of an abnormal protein that slows the growth of cancer c ells. This helps slow or stop the spread of cancer cells.

SUPPLIED AS : Erlocip is available as 150mg tablets.

OVERDOSE : Symptoms of overdose associated with Erlocip may include diarrhea and rash.

PRECAUTIONS & WARNINGS.

Erlocip should not be taken without consulting your doctor if you have liver disease or lung or breathing problems (other than lung cancer).
Take Erlocip several hours before or several hours after if you are taking antacids.
Do not take Erlocip if you are allergic to it or to any ingredient in Erlocip.
Do not take Erlocip without consulting your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with Erlocip. It is not known whether Erlocip passes into breast milk. Do not take Erlocip without first talking to your doctor if you are breast feeding a baby.

DRUG INTERACTIONS

The following drugs may interact with Erlocip:

nelfinavir, indinavir, saquinavir, ritonavir, rifampin, rifabutin, rifapentine, clarithromycin, nefazodone, telithromycin, troleandomycin, carbamazepine, phenytoin, ketoconazole, itraconazole, voriconazole..

SIDE EFFECTS

The side effects associated with Erlocip are difficulty breathing, closing of the throat, swelling of the lips, tongue, face or hives, shortness of breath, increased coughing, fever, chest pain, severe or persistent nausea, vomiting, loss of appetite, diarrhea, eye pain or irritation, skin rash, dryness, itching, acne, weakness, blistering, peeling, dry, or cracked skin, itching, tenderness, burning of the skin, growth of eyelashes on the inside of the eyelid, unusual bruising or bleeding.....

Note:Erlocip is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug...............

Targeted Cancer Therapy

ERLOCIP is specifically designed to target and block EGFR, an enzyme crucial in the development and progression of certain cancers. By inhibiting EGFR, this medication helps slow the growth and spread of cancer cells, offering a precision approach in oncology care.

Convenient Oral Administration

Administered orally, ERLOCIP allows patients to take their medication at home without the need for hospital-based intravenous treatments. Each blister pack ensures precise dosage and ease of use, supporting patient adherence to prescribed regimens.

Storage and Stability

The tablets should be stored in a dry place below 30C and protected from direct light to maintain their efficacy over 24 months. Proper storage ensures that the medicine remains potent and safe throughout its shelf life.

FAQs of ERLOCIP ERLOTINIB TABLETS:

Q: How should ERLOCIP Erlotinib Tablets be taken?

A: ERLOCIP tablets are intended for oral use and should be taken exactly as prescribed by your oncology specialist, usually once daily. Swallow the tablet whole with water, ideally on an empty stomach or at least one hour before eating.

Q: What is the principal benefit of using ERLOCIP in cancer treatment?

A: The primary benefit of ERLOCIP is its targeted mechanism, which inhibits the Epidermal Growth Factor Receptor (EGFR), essential for cancer cell growth. This specificity can improve treatment outcomes, particularly in cancers associated with EGFR mutations.

Q: When is ERLOCIP indicated during cancer therapy?

A: ERLOCIP is prescribed when cancer cells are identified as positive for EGFR mutations, often in cases of non-small cell lung cancer and other selected cancers. Your oncologist determines its suitability based on diagnostic results.

Q: Where can ERLOCIP 150 mg tablets be obtained?

A: ERLOCIP is available by prescription only and can be procured from certified distributors, exporters, suppliers, traders, and wholesalers across India, ensuring regulated access for patients in oncology treatment.

Q: What is the recommended storage condition for ERLOCIP tablets?

A: Store ERLOCIP tablets at temperatures below 30C, in a dry environment and away from direct light. This helps maintain the medications potency and extends its shelf life up to 24 months.

Q: How does ERLOCIP work within the body?

A: ERLOCIP acts by selectively inhibiting the enzymatic activity of EGFR. This interrupts the signaling pathways vital for cancer cell survival and proliferation, thereby reducing tumor growth.

Q: What is the process for patients to obtain a prescription for ERLOCIP?

A: A patient must undergo evaluation by an oncology specialist, including testing for EGFR mutations. If ERLOCIP is deemed appropriate, a prescription is provided, allowing the patient to purchase it from licensed outlets.

Tell us about your requirement